MIRA Pharmaceuticals, Inc..
MIRA.US | Research and experimental development on natural sciences and engineering
MIRA Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of novel therapies for neurological and psychiatric disorders. The company's primary focus is on developing drug candidates targeting the endocannabinoid system to treat conditions such as anxiety...Show More
Better Health for All
0
No evidence available to assess MIRA Pharmaceuticals, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
MIRA Pharmaceuticals, Inc. is a pharmaceutical company focused on research and development of novel therapies. The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, including underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its business model.
1
The company is also pre-revenue and unprofitable, with no evidence of community finance reinvestment or profit-sharing with underserved communities.
2
Fair Pay & Worker Respect
0
No evidence available to assess MIRA Pharmaceuticals, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
MIRA Pharmaceuticals, Inc. is focused on research and development activities and does not yet manufacture drugs for sale. This indicates that the company does not currently procure or trade physical commodities, nor does it have a significant supplier base or supply chain tiers that would require fair-trade certifications, sourcing audits, or remediation processes related to upstream labor practices or material risks. Consequently, metrics such as fair trade certification share, audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage in supplier contracts, materials risk index, and supplier diversity spend are not applicable to its current operational scope.
1
Honest & Fair Business
-50
MIRA Pharmaceuticals, Inc. made a payment of $148,703 for a short swing disgorgement related to a Section 16 claim as of June 30, 2024.
1
The company's disclosure controls and procedures were deemed ineffective as of June 30, 2024.
2
The company filed a Form 10-Q/A on August 16, 2024, which constitutes one financial restatement within the past three years.
3
The company's Code of Ethics and Conduct, approved June 27, 2023, includes a basic whistleblower policy that encourages reporting to various channels, protects confidentiality to the extent possible, and prohibits retaliation.
4
The Code also contains an anti-corruption policy that prohibits illegal payments to government officials of any country and giving anything of value to foreign government officials or political candidates to obtain or retain business.
5
Kind to Animals
0
No evidence available to assess MIRA Pharmaceuticals, Inc. on Kind to Animals.
No War, No Weapons
0
The provided articles focus on MIRA Pharmaceuticals, Inc.'s research and development in therapies for neurological and neuropsychiatric disorders and its internal business contracts. Both articles explicitly state that they do not contain any data relevant to the 'No War, No Weapons' value or the requested metrics.
1
Therefore, no specific, concrete data points are available to assess the company against any of the KPIs in the rubric.
Planet-Friendly Business
-30
The company diverted 51% of its waste from landfill in 2024.
1
No environmental compliance violations were reported.
2
Respect for Cultures & Communities
0
No evidence available to assess MIRA Pharmaceuticals, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
MIRA Pharmaceuticals states that no material cybersecurity incidents or threats have impacted the company, and it has not identified any past incidents.
1
The company claims compliance with CCPA and GDPR.
2
Users can update inaccurate account data, download stored data, request reports of personal information, access personal data, and request deletion of personal data, which results in account removal.
3
The privacy policy mentions collecting only necessary data, but specific data minimization practices or retention schedules are not detailed.
4
MIRA utilizes a multi-faceted approach to cybersecurity risk management, including third-party assessments, internal IT audits, governance reviews, and Coalition Control for proactive risk detection and mitigation.
5
It also assesses third-party risks and states it has processes to defend, detect, and respond to incidents.
6
The company conducts proactive reviews of systems and applications, audits data policies, and monitors relevant regulations.
7
Zero Waste & Sustainable Products
0
The provided articles do not contain any specific, concrete data points for MIRA Pharmaceuticals, Inc. regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1
The articles primarily discuss EU-wide regulations and general industry trends, explicitly stating a lack of company-specific data for MIRA.US on these metrics.
2